EX-10.53



 EXHIBIT 10.53 

CONFIDENTIAL TREATMENT REQUESTED 
  

 
 Manufacturing Agreement 

January 24, 2014 







 CONFIDENTIAL TREATMENT REQUESTED 

Table of Contents 
  

									
	ARTICLE 1	  	 	1	  
		
	INTERPRETATION	  	 	1	  
				
		 	1.1	 	DEFINITIONS.	  	 	1	  
		 	1.2	 	CURRENCY.	  	 	6	  
		 	1.3	 	SECTIONS AND HEADINGS.	  	 	6	  
		 	1.4	 	SINGULAR TERMS.	  	 	6	  
		 	1.5	 	SCHEDULES.	  	 	6	  
		
	ARTICLE 2	  	 	7	  
		
	PATHEON’S MANUFACTURING	  	 	7	  
				
		 	2.1	 	MANUFACTURING.	  	 	7	  
		 	2.2	 	ACTIVE MATERIAL YIELD.	  	 	10	  
		
	ARTICLE 3	  	 	12	  
		
	CLIENT’S OBLIGATIONS	  	 	12	  
				
		 	3.1	 	PAYMENT.	  	 	12	  
		 	3.2	 	SUPPLY OF ACTIVE MATERIALS.	  	 	12	  
		
	ARTICLE 4	  	 	13	  
		
	CONVERSION FEES AND COMPONENT COSTS	  	 	13	  
				
		 	4.1	 	PRICING.	  	 	13	  
		 	4.2	 	PRICE ADJUSTMENTS - SUBSEQUENT YEARS’ PRICING.	  	 	13	  
		 	4.3	 	PRICE ADJUSTMENTS – CURRENT YEAR PRICING.	  	 	15	  
		 	4.4	 	ADJUSTMENTS DUE TO TECHNICAL CHANGES.	  	 	16	  
		 	4.5	 	MULTI-COUNTRY PACKAGING REQUIREMENTS.	  	 	17	  
		 	4.6	 	IMPROVEMENT OF MANUFACTURING EFFICIENCY.	  	 	17	  
		
	 ARTICLE 5
	  	 	18	  
		
	ORDERS, SHIPMENT, INVOICING, PAYMENT	  	 	18	  
				
		 	5.1	 	ORDERS AND FORECASTS.	  	 	18	  
		 	5.2	 	RELIANCE BY PATHEON.	  	 	19	  
		 	5.3	 	MINIMUM ORDERS.	  	 	19	  
		 	5.4	 	SHIPMENTS.	  	 	20	  
		 	5.5	 	ON TIME DELIVERY.	  	 	20	  
		 	5.6	 	INVOICES AND PAYMENT.	  	 	21	  
		
	ARTICLE 6	  	 	21	  
		
	PRODUCT CLAIMS AND RECALLS	  	 	21	  
				
		 	6.1	 	PRODUCT CLAIMS.	  	 	21	  
		 	6.2	 	PRODUCT RECALLS AND RETURNS.	  	 	22	  
		 	6.3	 	PATHEON’S RESPONSIBILITY FOR DEFECTIVE AND RECALLED PRODUCTS.	  	 	23	  
		 	6.4	 	DISPOSITION OF DEFECTIVE OR RECALLED PRODUCTS.	  	 	24	  


  
 - i - 








 CONFIDENTIAL TREATMENT REQUESTED 

 

							
		 	6.5	 	CUSTOMER QUESTIONS AND COMPLAINTS.	  	24
		 	6.6	 	****.	  	24
		
	ARTICLE 7	  	25
		
	CO-OPERATION	  	25
				
		 	7.1	 	QUARTERLY REVIEW.	  	25
		 	7.2	 	GOVERNMENTAL AGENCIES.	  	25
		 	7.3	 	RECORDS AND ACCOUNTING BY PATHEON.	  	25
		 	7.4	 	INSPECTION.	  	25
		 	7.5	 	ACCESS.	  	26
		 	7.6	 	NOTIFICATION OF REGULATORY INSPECTIONS.	  	26
		 	7.7	 	REPORTS.	  	26
		 	7.8	 	FDA FILINGS.	  	27
		
	ARTICLE 8	  	28
		
	TERM AND TERMINATION	  	28
				
		 	8.1	 	INITIAL TERM.	  	28
		 	8.2	 	TERMINATION FOR CAUSE.	  	28
		 	8.3	 	OBLIGATIONS ON TERMINATION.	  	29
		
	ARTICLE 9	  	31
		
	REPRESENTATIONS, WARRANTIES AND COVENANTS	  	31
				
		 	9.1	 	AUTHORITY.	  	31
		 	9.2	 	CLIENT WARRANTIES.	  	31
		 	9.4	 	DEBARRED PERSONS.	  	33
		 	9.5	 	PERMITS.	  	33
		 	9.6	 	NO WARRANTY.	  	33
		
	ARTICLE 10	  	33
		
	REMEDIES AND INDEMNITIES	  	33
				
		 	10.1	 	CONSEQUENTIAL DAMAGES.	  	33
		 	10.2	 	LIMITATION OF LIABILITY.	  	34
		 	10.3	 	PATHEON.	  	34
		 	10.4	 	CLIENT.	  	34
		 	10.5	 	REASONABLE ALLOCATION OF RISK.	  	35
		
	ARTICLE 11	  	35
		
	CONFIDENTIALITY	  	35
				
		 	11.1	 	CONFIDENTIALITY.	  	35
		
	ARTICLE 12	  	37
		
	DISPUTE RESOLUTION	  	37
				
		 	12.1	 	COMMERCIAL DISPUTES.	  	37
		 	12.2	 	TECHNICAL DISPUTE RESOLUTION.	  	37

 ****CERTAIN INFORMATION HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE COMMISSION. 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS. 

  
 - ii - 








 CONFIDENTIAL TREATMENT REQUESTED 

 

									
		 	 12.3
	 	ARBITRATION.	  	 	38	  
		 	 12.4
	 	DISPUTE AND TERMINATION FOR BREACH.	  	 	38	  
		
	 ARTICLE 13
	  	 	38	  
		
	 MISCELLANEOUS
	  	 	38	  
				
		 	 13.1
	 	INVENTIONS.	  	 	38	  
		 	 13.2
	 	INTELLECTUAL PROPERTY.	  	 	39	  
		 	 13.3
	 	INSURANCE.	  	 	40	  
		 	 13.4
	 	INDEPENDENT CONTRACTORS.	  	 	40	  
		 	 13.5
	 	NO WAIVER.	  	 	40	  
		 	 13.6
	 	ASSIGNMENT.	  	 	40	  
		 	 13.7
	 	FORCE MAJEURE.	  	 	41	  
		 	 13.8
	 	ADDITIONAL PRODUCT.	  	 	41	  
		 	 13.9
	 	NOTICES.	  	 	42	  
		 	 13.10
	 	SEVERABILITY.	  	 	43	  
		 	 13.11
	 	ENTIRE AGREEMENT.	  	 	43	  
		 	 13.12
	 	OTHER TERMS.	  	 	43	  
		 	 13.13
	 	NO THIRD PARTY BENEFIT OR RIGHT.	  	 	43	  
		 	 13.14
	 	EXECUTION IN COUNTERPARTS.	  	 	43	  
		 	 13.15
	 	GOVERNING LAW.	  	 	43	  
		
	 SCHEDULE A
	  	 	45	  
		
	 SCHEDULE B
	  	 	46	  
		
	 SCHEDULE C
	  	 	50	  
		
	 SCHEDULE D
	  	 	51	  
		
	 SCHEDULE E
	  	 	52	  
		
	 SCHEDULE F
	  	 	53	  
		
	 SCHEDULE G
	  	 	55	  
		
	 SCHEDULE H
	  	 	56	  
		
	 SCHEDULE I
	  	 	57	  


  
 - iii - 









 EXHIBIT 10.53 

CONFIDENTIAL TREATMENT REQUESTED 
  

  

MANUFACTURING AGREEMENT 

THIS MANUFACTURING AGREEMENT (the “Agreement”) is made as of January 24, 2014 (the “Effective
Date”) 
 B E T W E E N: 
 PATHEON
PHARMACEUTICALS INC., 
 a corporation existing under the laws of 

the State of Delaware in the United States of America, 

(hereinafter referred to as “Patheon”), 

- and - 
 VANDA
PHARMACEUTICALS INC., 
 a corporation existing under the laws of the State of 

Delaware in the United States of America, 

(hereinafter referred to as the “Client”). 

THIS AGREEMENT WITNESSES THAT in consideration of the rights conferred and the obligations assumed herein, and for other good and valuable
consideration (the receipt and sufficiency of which are acknowledged by each party), and intending to be legally bound the parties agree as follows: 

ARTICLE 1 

INTERPRETATION 
  

	1.1	Definitions. 

 The following terms shall, unless the context otherwise requires,
have the respective meanings set out below and grammatical variations of such terms shall have corresponding meanings: 
 “Active
Materials” means the materials listed on Schedule D hereto; 
 “Active Materials Credit Value” means the value to
be attributed to the Active Materials for certain purposes of this Agreement, as set forth on Schedule D; 
 “Actual Annual
Yield” or “AAY” has the meaning specified in Section 2.2(a); 
 “Affiliate” means: 

  
 - 1 - 









 CONFIDENTIAL TREATMENT REQUESTED 

 


	 	(a)	a business entity which owns, directly or indirectly, a controlling interest in a party to this Agreement, by stock ownership or otherwise, only for so long as such ownership continues to exist; or 


 

	 	(b)	a business entity which is controlled by a party to this Agreement, either directly or indirectly, by stock ownership or otherwise, only for so long as such control continues to exist; or 


 

	 	(c)	a business entity, the controlling interest of which is directly or indirectly common to the majority ownership of a party to this Agreement, only for so long as such controlling interest continues to exist;


 For the purposes of this definition, “control” means the ownership of shares carrying at least a majority of the
votes in respect of the election of the directors of a corporation. 
 “Agreement” has the meaning specified in the
preamble; 
 “Annual Report” means the annual report to the FDA prepared by Client as described in Title 21 of the United
States Code of Federal Regulations, Section 314.81(b)(2); 
 “Annual Product Review Report” means the annual product
review report as described in Title 21 of the United States Code of Federal Regulations, Section 211.180(e); 
 “Annual
Volume” means the minimum volume of Product estimated to be manufactured in any Year of this Agreement as set forth in Schedule B hereto, which shall be prorated for the first Year of this Agreement; 

“Applicable Laws” means (i) with respect to Patheon, the Laws of the State of Ohio and the United States, being the
jurisdiction where the Manufacturing Site is located; and (ii) with respect to Client, the applicable Laws of all jurisdictions where the Products are manufactured, distributed and marketed; 

“Authority” means any governmental or regulatory authority, department, body or agency or any court, tribunal, bureau,
commission or other similar body, whether federal, state, provincial, county or municipal; 
 “Bill Back Items” means the
expenses for all third party supplier fees for the purchase or use of columns, standards, tooling, non-standard pallets, PAPR or PPE suits (where applicable), RFID tags and supporting equipment, and other project-specific items necessary for Patheon
to perform the Manufacturing Services, and which are not included as Components; 
 “Breach Notice” has the meaning
specified in Section 8.2(a); 

  
 - 2 - 









 CONFIDENTIAL TREATMENT REQUESTED 

 

 “Broader Intellectual Property Rights” has the meaning specified in
Section 13.1(c); 
 “Business Day” means a day other than a Saturday, Sunday or a day that is a statutory holiday in
the State of Ohio (with respect to Patheon only) or a day that is a statutory holiday in Washington, D.C. (with respect to Client only); 

“cGMPs” means current good manufacturing practices, regulations and guidelines as described in: 

 

	 	(a)	Division 2 of Part C of the Food and Drug Regulations (Canada); 

  

	 	(b)	Parts 210 and 211 of Title 21 of the United States’ Code of Federal Regulations; and 

  

	 	(c)	EC Directive 2003/94/EC, 

 together with the latest Health Canada, FDA and EMA guidance
documents pertaining to manufacturing and quality control practice, all as updated, amended and revised from time to time; 
 “Client
Property” has the meaning specified in Section 8.3(d); 
 “CMC” has the meaning specified in
Section 7.8(c); 
 “Components” means, collectively, all packaging components, raw materials and ingredients (including
labels, product inserts and other labelling for the Products), required to be used in order to produce the Products in accordance with the Specifications, other than the Active Materials; 

“Confidentiality Agreement” means the agreement relating to the non-disclosure of confidential information between Patheon and
the Client dated February 28, 2006 as amended September 28, 2009 and February 7, 2013. 
 “Conforming” with
respect to Product, means Product manufactured, packaged and stored by Patheon in accordance with the Specifications, cGMPs, Applicable Laws, the Quality Agreement and this Agreement. 

“Deficiencies” has the meaning specified in Section 7.8(d); 

“Deficiency Notice” shall have the meaning ascribed thereto in Section 6.1(a); 

“Delivery Date” has the meaning specified in Section 5.1(b); 

“Disclosure Obligations” has the meaning set forth in Section 11.1; 

“Effective Date” has the meaning specified in the preamble; 

“EMA” means the European Medicines Agency; 

  
 - 3 - 









 CONFIDENTIAL TREATMENT REQUESTED 

 

 “FDA” means the United States government department known as the Food and
Drug Administration; 
 “Firm Order(s)” has the meaning specified in Section 5.1(b); 

“Force Majeure Event” has the meaning specified in Section 13.7; 

“Health Canada” means the section of the Canadian Government known as Health Canada and includes, among other departments, the
Therapeutic Products Directorate and the Health Products and Food Branch Inspectorate; 
 “Initial Term” has the meaning
specified in Section 8.1; 
 “Intellectual Property” includes, without limitation, rights in patents, patent
applications, formulae, trade-marks, trade-mark applications, trade-names, Inventions, copyright and industrial designs and all other intellectual and industrial property rights of any sort throughout the world now known or hereafter recognized;

 “Invention” means any idea, concept, innovation, improvement, development, discovery, technology, computer program,
device, trade secret, work of authorship, formula, compound, method, know-how, process, technique or the like, whether or not written or otherwise fixed in any form or medium, regardless of the media on which it is contained and whether or not
patentable or copyrightable, that is conceived or reduced to practice by one or more person(s) in the course of the performance of this Agreement; 

“Inventory” means all inventories of Components and work-in-process produced or held by Patheon for the manufacture of the
Products but, for greater certainty, does not include the Active Materials; 
 “JAMS” means Judicial Arbitration and
Mediation Services, Inc.; 
 “Laws” means all laws, statutes, ordinances, regulations, rules, by-laws, judgments, decrees or
orders of any Authority; 
 “Manufacture or Manufacturing” means any one of more of the manufacturing, quality control,
quality assurance and stability testing, packaging and related services, as contemplated in this Agreement, required to produce Products from Active Materials and Components; 

“Manufacturing Site” means the facility owned and operated by Patheon that is located at 2110 E Galbraith Rd, Cincinnati,
OH 45237; 
 “Maximum Credit Value” means the maximum value of Active Materials that may be credited by Patheon
pursuant to this Agreement, as set forth on Schedule D; 
 “Minimum Order Quantity” means the minimum number of units of a
Product to be ordered in order to obtain the Price as set forth in Schedule B hereto. 

  
 - 4 - 









 CONFIDENTIAL TREATMENT REQUESTED 

 

 “MSDS” has the meaning specified in Section 5.2; 

“Order Countries” means, collectively, all countries in the Territory for which Client places Orders hereunder; 

“Patheon Requirement” has the meaning specified in 2.1(h); 

“Packaged Product(s)” means Product(s) packaged into primary and (where applicable) secondary packaging Components, including
printed packaging Components where specified; 
 “PPI” has the meaning specified in Section 4.2(a); 

“Product(s)” means the products listed on Schedule A hereto; 

“Product Claims” has the meaning specified in Section 6.3(c); 

“Quality Agreement” means the agreement dated August 22, 2013 between the parties hereto setting out the quality
assurance standards to be applicable to the Manufacturing performed by Patheon, which agreement is attached hereto as Schedule G; 

“Recall” has the meaning specified in Section 6.2(a); 

“Regulatory Authority” means the FDA, EMEA and Health Canada and any other foreign regulatory agencies competent to grant
marketing approvals for pharmaceutical products including the Products in the Territory; 
 “Remediation Period” has the
meaning specified in Section 8.2(a); 
 “SEC” has the meaning set forth in Section 11.1; 

“Specifications” means the file, for each Product, which is provided by the Client to Patheon in accordance with the
procedures listed in Schedule A hereto and which contains documents relating to such Product, including, without limitation: 
  

	 	(a)	specifications for Active Materials and Components; 

  

	 	(b)	Manufacturing specifications, directions and processes; 

  

	 	(c)	storage requirements; 

  

	 	(d)	all environmental, health and safety information relating to the Product including material safety data sheets; and 

  

	 	(e)	the finished Product specifications, packaging specifications and shipping requirements for each Product; 


  
 - 5 - 









 CONFIDENTIAL TREATMENT REQUESTED 

 

 all as updated, amended and revised from time to time by the Client in accordance with the
terms of this Agreement; 
 “Target Yield” has the meaning specified in Section 2.2(a); 

“Target Yield Determination Batches” has the meaning specified in Section 2.2(a); 

“Technical Dispute” has the meaning specified in Section 12.2; 

“Territory” means in the geographic area of the United States of America; 

“Third Party Rights” means the Intellectual Property of any third party; 

“Wind-Down Period” has the meaning specified in Section 8.3(d); 

“Year” means in the first year of this Agreement the period from the Effective Date up to and including December 31 of
the same calendar year, and thereafter shall mean a calendar year. 
  

	1.2	Currency. 

 Unless otherwise indicated, all monetary amounts are expressed in this
Agreement in the lawful currency of the United States of America. 
  

	1.3	Sections and Headings.  

 The division of this Agreement into Articles, sections,
subsections and Schedules and the insertion of headings are for convenience of reference only and shall not affect the interpretation of this Agreement. Unless otherwise indicated, any reference in this Agreement to a Section or Schedule refers to
the specified Section or Schedule to this Agreement. In this Agreement, the terms “this Agreement”, “hereof”, “herein”, “hereunder” and similar expressions refer to this Agreement
and not to any particular part, Section, Schedule or the provision hereof, and unless the context of this Agreement otherwise requires, “include”, “includes” and “including” are not
limiting. 
  

	1.4	Singular Terms. 

 Except as otherwise expressly
provided herein or unless the context otherwise requires, all references to the singular shall include the plural and vice versa. 
  

	1.5	Schedules. 

 The following Schedules are attached to, incorporated in and form
part of this Agreement: 

  
 - 6 - 









 CONFIDENTIAL TREATMENT REQUESTED 

 


					
	 Schedule A
	  		  	Product List
	 Schedule B
	  		  	Commercial Pricing
	 Schedule C
	  		  	Stability Testing
	 Schedule D
	  		  	Active Materials, Active Materials Credit Value & Maximum Credit Value
	 Schedule E
	  		  	Batch Numbering & Expiration Dates
	 Schedule F
	  	-	  	Technical Dispute Resolution
	 Schedule G
	  	-	  	Quality Agreement
			
	 Schedule H
	  	-	  	Quarterly Active Materials Inventory Report
	 Schedule I
	  	-	  	Report of Annual Active Materials Inventory Reconciliation and Calculation of Actual Annual Yield

 ARTICLE 2 

PATHEON’S MANUFACTURING 
  

	2.1	Manufacturing. 

 In accordance with Client’s Firm Orders, Patheon shall
perform Manufacturing for the Territory at the Manufacturing Site for the fees specified in Schedules B and C in order to produce Products for the Client. Patheon may change the Manufacturing Site for the Products ****. In providing the
Manufacturing, Patheon and the Client agree that: 
  

	 	(a)	Conversion of Active Materials and Components. Patheon shall convert Active Materials and Components into Products. 

  

	 	(b)	Quality Control and Quality Assurance. Patheon shall perform the quality control and quality assurance testing specified in the Quality Agreement. Batch review and release to the Client shall be the
responsibility of Patheon’s quality assurance group. Patheon shall perform its batch review and release responsibilities in accordance with Patheon’s standard operating procedures. Upon the Client’s request, Client may review
Patheon’s standard operating procedures at Patheon’s facility. Each time Patheon ships Products to the Client, it shall provide the Client, in English, a certificate of analysis and certificate of compliance including a statement that the
batch has been manufactured and tested in accordance with Specifications and cGMPs. The Client will have sole responsibility for the release of Products to the market. 


 

	 	(c)	Components. Patheon shall purchase all Components (with the exception of those that are supplied by the Client, which for certainty excludes Active Materials), in accordance with the Specifications. Patheon shall
test all Components and Active Materials in accordance with the Specifications. 


  
 - 7 - 

****CERTAIN INFORMATION HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 









 CONFIDENTIAL TREATMENT REQUESTED 

 


	 	(d)	Stability Testing. Patheon shall conduct stability testing on the Products in accordance with the protocols set out in Schedule C for the separate fees specified in Schedule C. Patheon shall not make any
changes to these testing protocols without prior written approval from the Client. In the event of a confirmed stability test failure, Patheon will notify the Client within ****, after which Patheon and the Client shall jointly determine the
proceedings and methods to be undertaken to investigate the causes of such failure, including which party shall bear the cost of such investigation; ****. Patheon will promptly provide any and all data and results relating to the stability testing
upon request by the Client. 

  

	 	(e)	Packaging. Patheon shall package the Products as set out in the Specifications. The Client shall be responsible for the cost of artwork development. Patheon shall make arrangements for and implement the
imprinting of batch numbers and expiration dates for each Product shipped. Such batch numbers and expiration dates shall be affixed on the Products and on the shipping carton of each Product as outlined in the Specifications and as required by
cGMPs. The system used by Patheon for batch numbering and expiration dates is detailed in Schedule E hereto. The Client may, in its sole discretion, make changes to labels, product inserts and other packaging for the Products, which changes
shall be submitted by the Client to all applicable governmental agencies and other third parties responsible for the approval of the Products. The Client shall be responsible for the cost of labelling obsolescence when changes occur, as contemplated
in Section 4.4. Patheon’s name shall not appear on the label or anywhere else on the Products unless: (i) required by any applicable Laws; or (ii) Patheon expressly consents to such use of its name in writing. 


 

	 	(f)	 Active Materials and Client Supplied Components. Client will **** deliver the Active Materials and any Client-supplied Components to the
Manufacturing Site DDP (Incoterms 2010) at least **** before the scheduled production date, at no cost to Patheon, in sufficient quantity to enable Patheon to manufacture the desired quantities of Product and to ship Product on the Delivery Date. If
the Active Materials and/or Client-supplied Components are not received at least **** before the scheduled production date, Patheon will make commercially reasonable efforts to expedite analytical testing at the Client’s expense to maintain the
scheduled production date. If the Active Materials and/or Client-supplied Components are not received at least **** before the scheduled production date and expedited release cannot be accomplished to maintain the scheduled production date (after
use of commercially reasonable efforts by Patheon), Patheon may **** 



  
 - 8 - 

****CERTAIN INFORMATION HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 









 CONFIDENTIAL TREATMENT REQUESTED 

 


	 	
****. ****. All shipments of Active Materials will be accompanied by certificate(s) of analysis from the Active Materials manufacturer and the Client, confirming the identity and purity of the
Active Materials and its compliance with the Active Materials specifications. 

  

	 	(g)	Bill Back Items. The expenses in respect of all third party supplier fees for the purchase of those items specifically identified in Schedule B that are necessary for Patheon to perform the Manufacturing (or
which are not included as Components or part of the Manufacturing fees in Schedule B), shall be charged to the Client ****. Any invoices for such items shall include reasonable documentation of the costs of such items. Any and all orders in excess
of **** for any such items require the prior written approval of the Client. 

  

	 	(h)	Requirements. Client hereby agrees to order **** of its total Yearly requirement in the Order Countries for new units of Products **** (the “Patheon Requirement”) from Patheon. However, Client
may order the Patheon Requirement, in whole or in part, from a third party supplier if Patheon ****. In addition, ****. Notwithstanding the foregoing, Patheon acknowledges and agrees that **** shall not be counted in determining Client’s
“total Yearly requirement in the Order Countries for new units of Products” (i.e., Client may ****). For the sake of clarity, during those Years in which Client orders Product from a third party supplier in accordance with the terms in
this subsection, then in no event shall Client be deemed to be in breach of this Section 2.1(h) if it does not purchase **** of its total Yearly requirement for new units of Products in the Order Countries from Patheon. 


  
 - 9 - 

****CERTAIN INFORMATION HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 









 CONFIDENTIAL TREATMENT REQUESTED 

 


	 	(i)	Product Rejection for Finished Product Specification Failure. Patheon shall manufacture Product in accordance with agreed upon Specifications, including Specifications for Patheon’s internal process. If
Patheon manufactures Product in accordance with the such Specifications, the batch production record, Patheon’s standard operating procedures for manufacturing (including, without limitation, for cleaning and calibration), all applicable laws,
this Agreement and the Quality Agreement, and **** Client will pay Patheon ****. The API in the non-conforming Product will ****. 

  

	 	(j)	Patheon shall maintain and service all equipment that Client has authorized Patheon to purchase on Client’s behalf, such equipment to be returned promptly by Patheon to Client in good working order, reasonable wear
and tear excepted, following the termination or expiration of this Agreement. Unless otherwise agreed in a separate written equipment agreement, Patheon shall not use all or any part of such equipment for any purpose other than supplying Product to
Client under this Agreement. 

  

	2.2	Active Material Yield. 

 (a) Reporting. Patheon shall provide the Client
with a quarterly inventory report of the Active Materials supplied by Client (if applicable) and held by Patheon in accordance with the inventory report form annexed hereto as Schedule H, which shall contain the following information for such
quarter: 
 Quantity Received: The total quantity of Active Materials that complies with the Specifications and is received at the
Manufacturing Site during the applicable period. 
 Quantity Dispensed: The total quantity of Active Materials dispensed at the
Manufacturing Site during the applicable period. The Quantity Dispensed is calculated by adding the Quantity Received to the inventory of Active Materials that complies with the Specifications and is held at the beginning of the applicable period,
less the inventory of Active Materials that complies with the Specifications and is held at the end of such period. The Quantity Dispensed shall only include Active Materials received and dispensed in connection with commercial manufacturing of any
Products and, for certainty, shall not include any (i) Active Materials that must be retained by Patheon as samples, (ii) Active Materials contained in any Product that must be retained as samples, (iii) Active Materials used in
connection with testing (if applicable) and (iv) Active Materials received or dispensed in connection with technical transfer activities or development activities during the applicable period, including, without limitation, any regulatory,
stability, validation or test batches manufactured during the applicable period. 

  
 - 10 - 

****CERTAIN INFORMATION HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 









 CONFIDENTIAL TREATMENT REQUESTED 

 

 Quantity Converted: The total amount of Active Materials contained in the Products
produced with the Quantity Dispensed (including any additional Products produced in accordance with Section 6.1 or 6.2 or 6.3), delivered by Patheon, and not rejected, recalled or returned in accordance with Section 6.1 or 6.2 as a result
of a failure by Patheon to provide Manufacturing in accordance with Specifications, cGMPs, Applicable Laws, the Quality Agreement or this Agreement. 

Patheon will target within ****, but within no more than **** after the **** of each ****, Patheon shall prepare an annual reconciliation of Active
Materials in accordance with the reconciliation report form annexed hereto as Schedule I including the calculation of the “Actual Annual Yield” or “AAY” for the Products (including all strengths) at the
Manufacturing Site during the Year. AAY is the percentage of the Quantity Dispensed that was converted to Products and is calculated as follows: 
  

					
	 Quantity Converted during the Year
	  	x	  	100%
	Quantity Dispensed during the Year	  		  	

 After ****, the Parties will mutually agree on the target yield in respect of the Products at the Manufacturing Site (a
“Target Yield”); provided, however, that ****. Thereafter, Patheon shall strive to maintain Actual Annual Yield levels for the Products equal to or above the Target Yield. For the sake of clarity, if applicable, the AAY and the
Target Yield are each calculated for ****.  
 (b) Shortfall Calculation. If the Actual Annual Yield falls **** below the
respective Target Yield in a Year, then the shortfall for such Year (the “Shortfall”) shall be determined based on the following calculation: 

Shortfall = **** 
 The Shortfall shall be
disclosed by Patheon on the reconciliation report prepared in the form annexed hereto as Schedule I. 
 (c) Credit. If there is a
Shortfall for the Products in a Year, then Patheon shall credit the Client’s account for the value of any such Shortfall, as determined using the following formula, not later than **** after the end of each Year. 

 

  
 - 11 - 

****CERTAIN INFORMATION HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 









 CONFIDENTIAL TREATMENT REQUESTED 

 

 **** 

Patheon acknowledges that such credit is a liquidated damage reflecting a reasonable measure of actual damages and is not a penalty. Each credit under this
Section 2.2 shall be summarized on the reconciliation report prepared in the form annexed hereto as Schedule I and shall be made not later than **** after the end of each Year. Upon expiration or termination of this Agreement any remaining
credit amount owing under this Section 2.2 (or other Section under this Agreement) shall be reimbursed to the Client by payment thereof to the Client. 

(d) ****. Notwithstanding the foregoing provisions of this Section 2.2, Patheon’s liability for Active Materials calculated
in accordance with Section 2.2(c) for the Products in a Year ****. 
 (e) No Material Breach. It shall not constitute a material
breach of this Agreement by Patheon, for the purposes of
 Section 8.2(a), if ****. 
 ARTICLE 3 

CLIENT’S OBLIGATIONS 
  

	3.1	Payment. 

 Pursuant to the terms of this Agreement, the Client shall pay Patheon
for the provision of the Manufacturing according to the fees specified in Schedules B and C hereto (such fees being subject to adjustment in accordance with the terms hereof). 

 

	3.2	Supply of Active Materials. 

 Client shall, at its sole cost and expense,
deliver the Active Materials to Patheon (in accordance with Section 2.1(f)) in sufficient quantities and at such times as mutually agreed upon by the parties to facilitate the provision of the Manufacturing by Patheon. Client’s obligation
will include obtaining the proper release of the Active Materials from the applicable Customs Agency and Regulatory Authority. Client or Client’s designated broker will be the “Importer of Record” for Active Materials imported
to the Manufacturing Site. The Active Materials shall be held and stored by Patheon on behalf of the Client on the terms and subject to the conditions herein contained, the Specifications, cGMPs and any written instructions provided by the Client to
Patheon from time to time. Title to the Active Materials shall at all times belong to and remain the property of the Client. Any Active Materials received by Patheon shall only be used by Patheon to provide the Manufacturing. Patheon will not
chemically or biologically modify the Active Materials except in accordance with the Specifications. Patheon’s liability with respect to any lost or damaged Active Materials shall be as set forth in Section 10.2(a). 

  
 - 12 - 

****CERTAIN INFORMATION HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 









 CONFIDENTIAL TREATMENT REQUESTED 

 

 If Client asks Patheon to qualify an additional source for the Active Material or any
Component, Patheon will evaluate the Active Material or Component to be supplied by the additional source to determine if it is suitable for use in the Product. The parties will agree on the scope of work to be performed by Patheon at Client’s
cost. For an Active Material, this work at a minimum will include: 
  

	 	(a)	laboratory testing to confirm the Active Material meets existing specifications; 

  

	 	(b)	manufacture of an experimental batch of Product that will be placed on **** accelerated stability; and 

  

	 	(c)	manufacture of **** full-scale validation batches that will be placed on concurrent stability (one batch may be the registration batch if manufactured at full scale). 


Section 2.1(i) will apply to all Product manufactured using the newly approved Active Material or Component because of the limited
material characterization that is performed on additional sources of supply. 
 ARTICLE 4 

CONVERSION FEES AND COMPONENT COSTS 
  

	4.1	Pricing. 

 The fees for the Manufacturing through **** are listed in
Schedules B and C and are subject to the adjustments set forth in Section 4.3. 
  

	4.2	Price Adjustments - Subsequent Years’ Pricing. 

 The fees for the
Manufacturing during any period following the **** shall be determined in accordance with the following: 
 (a) Manufacturing and
Component Costs. On each **** of this Agreement, Patheon and the Client shall be entitled to an adjustment to the fees (i) for Manufacturing in respect of the Products to reflect inflation, which adjustment shall be solely based on ****,
unless the parties otherwise agree in writing and (ii) for Component costs ****. 

  
 - 13 - 

****CERTAIN INFORMATION HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 









 CONFIDENTIAL TREATMENT REQUESTED 

 


	 	(b)	Annual Quantity. 

 The Client acknowledges that the fee for Manufacturing in respect of a
Product in any Year is quoted based upon the Annual Volume and Minimum Order Quantity per Product specified in Schedule B and is subject to change following good faith discussions by the parties if the specified Annual Volume or Minimum Order
Quantity increases or decreases. For greater certainty, if Patheon and the Client agree that the Annual Volume or Minimum Order Quantity in respect of a Product shall be reduced beyond the range of such values provided in the tables in Schedule B,
whether as a result of a decrease in estimated annual volume or otherwise, and, as a result of such reduction, Patheon’s costs for services relating to such Product increase on a per unit basis, then Patheon shall be entitled to an increase in
the fee for Manufacturing in respect of such Product. In addition, for greater certainty, if Patheon and the Client agree that the Annual Volume or Minimum Order Quantity in respect of a Product shall be increased beyond the range of such values
provided in the tables in Schedule B, and, as a result of such increase, Patheon’s costs for services relating to such Product decrease on a per unit basis, then the Client shall be entitled to a decrease in the fee for Manufacturing in respect
of such Product. 
 In connection with all fee adjustments requests pursuant to this Section 4.2, Patheon shall deliver to the Client by not later than
**** of each **** a revised Schedule B in draft form and such budgetary pricing information or other documentation reasonably sufficient to demonstrate that an increase or decrease in the fee adjustment is justified (and/or upon the reasonable
request of Client, such budgetary pricing information or other documentation reasonably sufficient to demonstrate to Client that a decrease in the fee adjustment is not justified), provided that to the extent such documents are subject to
obligations of confidentiality between Patheon and its suppliers, Patheon shall make such documents available, subject to the confidentiality obligations provided in this Agreement, to a third party designated by Client and approved by Patheon (such
approval not to be unreasonably withheld or delayed) at Patheon’s facility for the purpose of allowing such third party to confirm that the fee adjustments proposed by Patheon are justified. Upon delivery of such a fee adjustment request
pursuant to this Section, each of the Client and Patheon shall forthwith use reasonable efforts to agree on a revised fee for the Manufacturing in respect of each affected Product, if any, and Schedule B shall be amended accordingly. If the parties
are unable to agree on a revised fee for the Manufacturing in respect of each affected Product within **** after receipt by Client of Patheon’s fee adjustment request, then ****. The revised fee shall be effective with respect to any Product
ordered after the end of the then current ****. 

  
 - 14 - 

****CERTAIN INFORMATION HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 









 CONFIDENTIAL TREATMENT REQUESTED 

 


	4.3	Price Adjustments – Current Year Pricing. 

 During any Year of
this Agreement, the fees set out in Schedule B shall be subject to adjustment in accordance with the following: 
 (a) Annual
Quantity. If at any time and from time to time Patheon or Client determines, acting reasonably and based on the forecasts and Firm Orders received from the Client, that the current Annual Volume or Minimum Order Quantity listed in Schedule B for
each specific Product strength will either not be met or will be exceeded (i.e., the actual Minimum Order Quantity and/or the actual Annual Volume, and the costs of such variations, exceed the range of such value(s) provided in the tables in
Schedule B), then Patheon or Client shall be entitled to request an adjustment to the fee for Manufacturing in respect of that Product to reflect the increased or decreased costs that Patheon will incur as a result of the increased or reduced
volumes beyond the range of such values provided in the tables in Schedule B. To the extent that the fee for Manufacturing in respect of a Product has been previously adjusted pursuant to this clause (a) to reflect reduced volumes or increased
volumes, the adjustment provided in this clause (a) shall operate based on the fees attributed to such Product at the time the last of such adjustments were made. 

(b) Extraordinary Increase in Component Costs. If at any time market conditions result in Patheon’s cost of Components being ****
greater than normal forecasted increases, then Patheon shall be entitled to an adjustment to the fee for Manufacturing in respect of any affected Product solely to compensate it for such increased Component costs that may be justified by reasonable
documentation, provided that to the extent such documents are subject to obligations of confidentiality between Patheon and its suppliers, Patheon shall make such documents available, subject to the confidentiality obligations provided in this
Agreement, to a third party designated by Client and approved by Patheon (such approval not to be unreasonably withheld or delayed) at Patheon’s facility for the purpose of allowing such third party to confirm that the fee adjustments proposed
by Patheon are justified. For the purposes of this clause (b), changes materially greater than normal forecasted increases shall be considered to have occurred only if ****. To the extent that Component costs have been previously adjusted pursuant
to clause (a) of Section 4.2 or this clause (b) to reflect an increase in the cost of one or more Components, the adjustments provided for in (i) and (ii) above shall operate based on the costs attributed to such Component
(or Components) at the time the last of such adjustments were made. 
 In connection with a fee adjustment request pursuant to this
Section 4.3, Patheon shall deliver to the Client a revised Schedule B and such budgetary pricing information, adjusted Component costs or other documentation reasonably sufficient to demonstrate that an increase or decrease in fee adjustment is
justified 

  
 - 15 - 

****CERTAIN INFORMATION HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 









 CONFIDENTIAL TREATMENT REQUESTED 

 

 (and/or upon the reasonable request of Client, such budgetary pricing information or other
documentation reasonably sufficient to demonstrate to Client that a decrease in the fee adjustment is not justified), provided that to the extent such documents are subject to obligations of confidentiality between Patheon and its suppliers, Patheon
shall make such documents available, subject to the confidentiality obligations provided in this Agreement, to a third party designated by Client and approved by Patheon (such approval not to be unreasonably withheld or delayed) at Patheon’s
facility for the purpose of allowing such third party to confirm that the fee adjustments proposed by Patheon are justified. Upon delivery of such a request, each of the Client and Patheon shall forthwith use all reasonable efforts to agree on a
revised fee for the Manufacturing in respect of each affected Product and Schedule B shall be amended accordingly. If the parties are unable to agree on a revised fee for the Manufacturing in respect of each affected Product within **** after
receipt by Client of Patheon’s fee adjustment request, then ****. 
 Patheon will use commercially reasonable efforts to ensure that the
increases in cost of Components will not be materially greater than normal forecasted increases. 
  

	4.4	Adjustments Due to Technical Changes. 

 Amendments to the Specifications or the
Quality Agreement requested by the Client will only be implemented following a good faith technical and cost review by Patheon and are subject to the Client and Patheon reaching agreement in writing as to revisions, if any, to the fees specified in
Schedules B or C necessitated by any such amendment. Amendments to the Specifications, the Quality Agreement or the Manufacturing Site or any material deviations from the assumptions specified in Schedule B requested by Patheon will only be
implemented following the written approval of Client, such approval not to be unreasonably withheld. If the Client accepts the proposed fee change (if any), the proposed change in the Specifications or the Quality Agreement requested by Client shall
be implemented, and the fee change shall become effective only with respect to those orders of Products that are manufactured in accordance with the revised Specifications or Quality Agreement. In addition, the Client agrees ****. Open purchase
orders for Components no longer required under 

  
 - 16 - 

****CERTAIN INFORMATION HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 









 CONFIDENTIAL TREATMENT REQUESTED 

 

 
any revised Specifications or Quality Agreement that were placed by Patheon with suppliers in order to fill Firm Orders or in accordance with Section 5.2 shall be cancelled or used in
connection with other Patheon services where possible, and where such orders are not subject to cancellation without penalty or cannot be used in connection with other Patheon services, Client shall pay to Patheon ****. 

 

	4.5	Multi-Country Packaging Requirements.  

 Prices in Schedule B are for Packaged
Product(s) for the specific markets in the Territory requested by Client. Should Client wish to have Patheon provide Manufacturing in respect of the Product for countries in addition to those countries listed in Schedule B, then the Client shall
inform Patheon of the packaging requirements for each new country and Patheon shall, in good faith, prepare a quotation for consideration by the Client of the additional Component costs, if any, and the change over fees for the Product destined for
each such new country. The agreed additional packaging requirements and related packaging costs and change over fees shall be set out in a written amendment to this Agreement mutually agreed upon by the parties. 

 

	4.6	Improvement of Manufacturing Efficiency. 

 Each
of Patheon and the Client shall use its reasonable efforts to improve Product manufacturing efficiency, when and where possible, during the term of this Agreement. Any cost savings resulting in whole or in part from contributions by the Client shall
be ****. 

  
 - 17 - 

****CERTAIN INFORMATION HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 









 CONFIDENTIAL TREATMENT REQUESTED 

 

 ARTICLE 5 

ORDERS, SHIPMENT, INVOICING, PAYMENT 
  

	5.1	Orders and Forecasts. 

 (a) Rolling Forecasts. Concurrent with the
execution of this Agreement, the Client shall provide Patheon with a written **** forecast of the volume of each Product that the Client then anticipates will be required to be produced and delivered to the Client during ****. Such forecast will be
updated by the Client **** on or before the **** of each **** on a ****, and the Client shall use commercially reasonable efforts to update such forecast forthwith if the Client determines that the volumes contemplated in the most recent of such
forecasts for the next **** have changed by more than ****. The most recent **** forecast shall prevail. 
 (b) Firm Orders. On or
before the **** of each ****, the Client shall issue a firm written order (“Firm Order”) for Manufacturing in respect of the Products to be produced and delivered to the Client on one or more dates not less than**** from the first
day of the calendar month immediately following the date that the Firm Order is submitted (each, a “Delivery Date”). Such Firm Orders submitted to Patheon shall specify the Client’s Manufacturing purchase order number,
quantities by Product type, monthly delivery schedule, shipment location and any other elements necessary to ensure the timely production and shipment of the Products. The quantities of Products ordered in such Firm Orders shall be ****. If Client
cancels any or part of a Firm Order, Client shall be responsible for **** of such cancelled part of a Firm Order, provided that if Client informs Patheon at any time during the **** of this Agreement, at **** prior to the Delivery Date of any Firm
Order, that it would like to cancel any or part of such Firm Order, then ****. ****. Patheon shall indicate its acceptance of Firm Orders for the Product by promptly acknowledging acceptance of each Firm Order in writing within **** of its receipt;
each such acceptance shall include, subject to Client confirmation, the Delivery Date for the Product ordered. The agreed upon Delivery Date may be amended from time to time by written agreement of the parties, with the newly agreed upon date
becoming the new Delivery Date. For the avoidance of doubt, Patheon will accept all Firm Orders submitted by the Client for Product so long as ****. **** 

  
 - 18 - 

****CERTAIN INFORMATION HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 









 CONFIDENTIAL TREATMENT REQUESTED 

 

 ****. All Firm Orders will be deemed to incorporate all of the terms and conditions in this
Agreement. 
 (c) **** Forecast. On or before the **** of **** of each ****, the Client shall provide Patheon with a written ****
forecast (broken down by ****) of the volume of each Product the Client then anticipates will be required to be produced and delivered to the Client during the ****. 
  

	5.2	Reliance by Patheon. 

 The Client understands and acknowledges that Patheon will
rely on the Firm Orders and rolling forecasts submitted pursuant to Sections 5.1(a) and (b) in ordering the Components required to meet such Firm Orders. In addition, the Client understands that to ensure an orderly supply of such Components
and/or to achieve economies of scale in costs, it may be necessary for Patheon to purchase such Components in sufficient volumes to meet the production requirements for Products during part of the forecasted periods referred to in
Section 5.1(a) or to meet the production requirements of any longer period agreed to in writing by Patheon and the Client. Accordingly, the Client authorizes Patheon to purchase Components in order to satisfy the Manufacturing requirements for
Products for the **** contemplated in the most recent forecast provided by the Client pursuant to Section 5.1(a) and agrees that Patheon may make such other purchases of Components to meet Manufacturing requirements during such longer periods
as may be agreed to in writing from time to time by the Client at the request of Patheon or the Client. If Components of the Product unique to the Client (e.g., packaging labels), ordered by Patheon pursuant to Firm Orders or this Section 5.2
are not included in finished Products manufactured for the Client within **** after the forecasted month in respect of which such purchases have been made (or such longer period as the parties may agree) or if such unique Components have expired
during such period, then the Client shall pay to Patheon ****. Patheon shall be responsible for obtaining material safety data sheets (“MSDS”) of all Components purchased by Patheon pursuant to this Agreement. The MSDS will be used to
establish conformance of the Components to the Specifications and to advise Patheon as to any safety or special handling requirements related to the Components. 
  

	5.3	Minimum Orders. 

 The Client may only order Manufacturing in respect of batches of
Products in multiples of the Minimum Order Quantities as set out in Schedule B. 

  
 - 19 - 

****CERTAIN INFORMATION HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 









 CONFIDENTIAL TREATMENT REQUESTED 

 


	5.4	Shipments. 

 Shipments of Products shall be made ****, unless otherwise mutually
agreed in writing. Risk of loss or of damage to Products shall remain with **** at which time risk of loss or damage (and title to such Products) shall transfer to ****. **** shall, in accordance with ****, (i) arrange for shipping to be paid
by **** and (ii) at **** risk and expense, obtain any export license or other official authorization necessary to export the Products. **** shall arrange for insurance and shall select the freight carrier to be used by **** to ship Products and
may monitor **** shipping and freight practices as they pertain to this Agreement. Products shall be packaged for transport and transported in accordance with the Specifications. 

 

	5.5	On Time Delivery. 

 (a) Patheon shall ****. Patheon and the Client understand that
there may be uncertainties and necessary adjustments associated with any initial manufacturing period and the parties agree that they will work together closely to expedite deliveries and manage the scheduling of the initial Product launch. 

(b) If subsequent to the creation of a delivery plan, Patheon is unable to supply the Client with the quantity of Product ordered pursuant to
the Firm Order by **** following the Delivery Date ****, then that inability to supply will constitute a late delivery of Product (“Late Delivery”), and the Client ****. If the parties mutually agree in writing to change the
Delivery Date for any reason, then that new date becomes the Delivery Date. 
 ****. In no event shall the Late Delivery ****. Patheon acknowledges that
****. No credit for Late Delivery will occur if the Late Delivery is caused by a Force Majeure Event (as defined below) or by other events outside of Patheon’s reasonable control, including, but not limited to, delays in: **** 

  
 - 20 - 

****CERTAIN INFORMATION HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 









 CONFIDENTIAL TREATMENT REQUESTED 

 

 ****. Additionally, on time delivery credits provided for in this Section are only available to Client if
****. 
  

	5.6	Invoices and Payment. 

 Invoices shall be sent by fax or email to such fax number or email address
as may be provided by the Client in writing from time to time. Such invoices for Products may only be sent **** (with respect to which such invoices apply) in accordance with the Quality Agreement, and such invoices shall reflect any outstanding
credit amounts owed under this Agreement by Patheon to Client. Patheon shall also submit to the Client, with each shipment of Products, a duplicate copy of the invoice covering such shipment. Patheon shall also provide the Client with an invoice
covering any Inventory or Components which are to be purchased by Patheon pursuant to the terms of this Agreement. Each such invoice shall, to the extent applicable, identify the Client’s Manufacturing purchase order number, Product numbers,
names and quantities, unit price, freight charges and the total amount to be remitted by the Client (after taking into account any outstanding credit amounts owed under this Agreement by Patheon to Client). The Client shall pay all such undisputed
invoices within **** of the date thereof, provided, however, that payment will only be for ****. ****. ****. Patheon shall fax or email a copy of the invoice to fax number or email address provided by Client on the date of invoice 

ARTICLE 6 
 PRODUCT
CLAIMS AND RECALLS 
  

	6.1	Product Claims. 

 (a) Product Claims. The Client has the right to reject
any portion of any shipment of Products that deviates from **** without invalidating any remainder of such shipment. The Client shall inspect the Products manufactured by Patheon upon receipt thereof and shall give Patheon written notice (a
“Deficiency Notice”) of all claims for Products that deviate from **** within **** after the Client’s receipt thereof (or, in the case of any defects not reasonably susceptible to discovery upon receipt of the Product, within ****
after discovery thereof by the Client, but in no event after the expiration date of the Product). Should the Client fail to provide Patheon with the Deficiency Notice within the applicable period, then the delivery shall be deemed to have been
accepted by the Client on the **** after delivery or **** after discovery, as applicable. Except as otherwise provided in this Agreement, Patheon shall have no 

  
 - 21 - 

****CERTAIN INFORMATION HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 









 CONFIDENTIAL TREATMENT REQUESTED 

 

 
liability for any deviations for which it has not received notice within the applicable period. For the sake of clarity, if the Client does not provide a Deficiency Notice within **** after
Client’s receipt of the applicable Product, but instead provides a Deficiency Notice within **** after discovery of a defect not reasonably susceptible to discovery upon receipt of the Product, then Client retains its rights and remedies with
respect to the defective Product. 
 (b) Determination of Deficiency. Upon receipt of a Deficiency Notice, Patheon shall have **** to
advise the Client by notice in writing that it disagrees with the contents of such Deficiency Notice. If the Client and Patheon fail, after good faith discussions, to agree within **** after Patheon’s notice to the Client as to whether any
Products identified in the Deficiency Notice deviate from ****, then the parties shall mutually select an independent laboratory to evaluate if the Products deviate from ****. Such evaluation shall be binding on the parties, and if such evaluation
certifies that any Products deviate from ****, the Client may reject those Products in the manner contemplated in this Section 6.1. If such evaluation does not so certify in respect of any such Products, then the Client shall be deemed to have
accepted delivery of such Products on the **** after delivery (or, in the case of any defects not reasonably susceptible to discovery upon receipt of the Product, on the **** after discovery thereof by the Client, but in no event after the
expiration date of the Product). The decision of the laboratory shall be binding on the parties, and the party that the decision disfavours shall bear the costs charged by such laboratory in connection with its decision. 

(c) Shortages. Claims for shortages in the amount of Products shipped by Patheon shall be dealt with as may reasonably be agreed to by
the parties. 
  

	6.2	Product Recalls and Returns. 

 (a) Records and Notice. **** shall each
maintain such records as may be necessary to permit a Recall (as defined below) of any Products delivered to the Client or customers of the Client. **** shall promptly notify **** by telephone (to be confirmed in writing) of any information which is
reasonably likely to adversely affect the marketability, safety or effectiveness of the Products in a material manner and/or which might result in the Recall or seizure of the Products. Upon receiving any such notice or upon any such discovery, ****
shall cease and desist from further shipments of such Products in its possession or control until a decision has been made whether a Recall or some other corrective action is necessary. The decision to initiate a Recall or to take some other
corrective action, if any, shall be made and implemented by ****. “Recall” shall mean any action (i) by the Client to recover title to or possession of quantities of the Products sold or shipped to third parties (including,
without limitation, the voluntary withdrawal of Products from the market); or (ii) by any regulatory authorities to detain or destroy any of the Products. Recall shall also include any action by either party to refrain from selling or shipping
quantities of the Products to third parties which would have been subject to a Recall if sold or shipped. 

  
 - 22 - 

****CERTAIN INFORMATION HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 









 CONFIDENTIAL TREATMENT REQUESTED 

 

 (b) Recalls. If: (i) any governmental or regulatory authority issues a directive,
order or, following the issuance of a safety warning or alert with respect to a Product, a written request that any Product be Recalled, (ii) a court of competent jurisdiction orders such a Recall, or (iii) **** determines that any Product
should be Recalled or that a “dear doctor” letter is required relating to the restrictions on the use of any Product, **** will co-operate as reasonably required by ****, having regard to all applicable laws and regulations. 

(c) Product Returns. **** shall have the responsibility for handling customer returns of the Products. **** shall provide **** with
such assistance as **** may reasonably require to handle such returns. 
  

	6.3	Patheon’s Responsibility for Defective and Recalled Products. 

 (a)
Defective Product. If the Client rejects Products in accordance with Section 6.1 and the deviation is determined to have arisen from Patheon’s failure to provide the Manufacturing in accordance with ****, Patheon shall promptly,
****. For greater certainty, Patheon’s responsibility for ****. 
 (b) Recalled Product. To the extent that a Recall results
from, or arises out of, a failure by Patheon to provide the Manufacturing in accordance with ****, Patheon shall be responsible for ****. For greater certainty, Patheon’s responsibility for ****. If Patheon is unable to replace the Recalled
Products, then the Client may request Patheon to ****. In all other circumstances, Recalls shall be made at the Client’s cost and expense. 

(c) Patheon shall have no obligation for any deficiencies in, or other liabilities associated with, any Product manufactured by it
(collectively, “Product Claims”) to the extent such Product Claim **** 

  
 - 23 - 

****CERTAIN INFORMATION HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 









 CONFIDENTIAL TREATMENT REQUESTED 

 

 ****. 
  

	6.4	Disposition of Defective or Recalled Products. 

 The Client shall not dispose of
any damaged, defective, returned or Recalled Products in relation to which it intends to assert a claim against Patheon without Patheon’s prior written authorization to do so. Alternatively, Patheon may instruct the Client to return such
Products to Patheon. Patheon shall bear the cost of disposition with respect to any damaged, defective, returned or Recalled Products in relation to which it bears responsibility under Section 6.3 hereof. In all other circumstances, the Client
shall bear the cost of disposition, including all applicable fees for Manufacturing, with respect to any damaged, defective, returned or Recalled Products. 
  

	6.5	Customer Questions and Complaints. 

 The Client shall have the sole responsibility
for responding to questions and complaints from the Client’s customers. Questions or complaints received by Patheon from the Client’s customers shall be promptly referred to the Client. Patheon shall cooperate as reasonably required to
allow the Client to determine the cause of and resolve any customer questions and complaints. Such assistance shall include follow-up investigations, including testing. In addition, Patheon shall promptly provide the Client with all mutually agreed
upon information that will enable the Client to respond properly to questions or complaints relating to the Products as provided in the Quality Agreement. Unless it is determined that the cause of any customer complaint resulted from a failure by
Patheon to provide the Manufacturing in accordance with ****. 
  

	6.6	****. 

 ****. 

  
 - 24 - 

****CERTAIN INFORMATION HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 









 CONFIDENTIAL TREATMENT REQUESTED 

 

 ARTICLE 7 

CO-OPERATION 
  

	7.1	Quarterly Review. 

 Each party shall forthwith upon execution of this Agreement
appoint one of its employees to be a relationship manager responsible for liaison between the parties. The relationship managers shall meet not less than **** to review the current status of the business relationship and manage any issues that have
arisen. Each party may replace its relationship manager at any time and will fill a vacancy for its relationship manager as soon as reasonably practicable. Each party shall promptly notify the other party of any substitution of another person as its
relationship manager. Each party’s relationship manager shall be available throughout the term of this Agreement to answer any reasonable questions from the other party’s relationship manager. 

 

	7.2	Governmental Agencies. 

 Client may communicate with any governmental agency,
including but not limited to governmental agencies responsible for granting regulatory approval for the Products, regarding Product specific issues. Subject to Section 7.8, Patheon may communicate with any governmental agency, including but not
limited to governmental agencies responsible for granting regulatory approval for the Products, regarding Product specific issues, if ****. 
  

	7.3	Records and Accounting by Patheon. 

 Patheon shall keep records of the
Manufacture, testing and shipping of the Products, and retain samples of such Products as are necessary to comply with manufacturing regulatory requirements applicable to Patheon, as well as to assist with resolving Product complaints and other
similar investigations. Copies of such records and samples shall be retained for a period of **** following the date of Product expiry, or longer if required by law, at which time the Client will be contacted in writing concerning the delivery and
destruction of such documents and/or Products, ****. The Client is responsible for retaining samples of the Products necessary to comply with the legal/regulatory requirements applicable to the Client. 

 

	7.4	Inspection. 

 During the term of this Agreement and for **** thereafter, or
alternatively the period of time less than **** in which Patheon is required to keep reports and records pursuant to Section 7.3, the Client may inspect Patheon reports and records relating to 

  
 - 25 - 

****CERTAIN INFORMATION HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 









 CONFIDENTIAL TREATMENT REQUESTED 

 

 
this Agreement, including without limitation relating to the invoices issued hereunder, during normal business hours and with reasonable advance notice, provided a Patheon representative is
present during any such inspection. 
  

	7.5	Access. 

 Patheon shall provide the Client with reasonable access at mutually
agreeable times (as discussed in good faith) to the areas of the Manufacturing Site in which the Products are manufactured, stored, handled or shipped in order to permit the Client’s verification of the performance of the Manufacturing in
accordance with the Specifications, cGMPs, Applicable Laws, the Quality Agreement and this Agreement. For greater certainty, the right of access provided in this Section 7.5 shall not include a right to access or inspect Patheon’s
financial records. 
  

	7.6	Notification of Regulatory Inspections. 

 In accordance with applicable laws and
regulations governing regulatory inspections, and without waiving any rights and protections afforded Patheon under such laws and regulations, Patheon shall permit authorized representatives of relevant regulatory authorities, including the FDA, to
inspect any plant and production facilities (including the Manufacturing Site) relating to or used in connection with the Manufacturing and/or the Product. Patheon shall notify the Client within **** of any inspections by any governmental agency
that may bear directly on the Products. ****. 
  

	7.7	Reports. 

 Patheon will supply on an annual basis the Annual Product Review
Report. Patheon will also supply on an annual basis or as requested by Client at any other time all Product data in its control, including release test results, complaint test results, and all investigations (in manufacturing, testing and storage),
that the Client reasonably requires in order to complete any filing under any applicable regulatory regime, including any Annual Report that the Client is required to file with the FDA. Any additional reports requested by Client beyond the scope of
cGMPs and customary FDA requirements will be subject to an additional fee to be agreed upon in writing. All rights, title and interest in any and all data related to Product that is generated or derived by Patheon in the course of performing the
Manufacturing shall be the exclusive property of **** (and the confidential information of ****). **** hereby makes, and agrees to make, any and all assignments necessary to effect, exclusively and throughout the world, the ownership by **** of such
data. **** shall, and shall cause its employees and contractors to, fully cooperate with and sign any documents reasonably requested by **** to 

  
 - 26 - 

****CERTAIN INFORMATION HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 









 CONFIDENTIAL TREATMENT REQUESTED 

 

 
evidence, perfect or take any other action with respect to such assignments or to obtain protection, maintain or take any other action regarding such assigned data. 

 

	7.8	FDA Filings. 

 (a) Regulatory Authority. The Client shall have the sole
responsibility for filing all documents with all Regulatory Authorities and taking any other actions that may be required for the receipt and/or maintenance of Regulatory Authority approval for the commercial manufacture of the Products. Patheon
shall assist the Client, as is reasonable, to obtain Regulatory Authority approval for the commercial Manufacture of all Products as quickly as reasonably possible. 

(b) Verification of Data. At least **** prior to filing any documents with any Regulatory Authority that incorporate data generated by
Patheon, the Client shall ****. 
 (c) Verification of CMC. At least **** prior to filing with any Regulatory Authority any
documentation which is or is equivalent to the FDA’s Chemistry and Manufacturing Controls (“CMC”) related to any Marketing Authorization, such as a New Drug Application or Abbreviated New Drug Application, the Client shall
****. 
 (d) Deficiencies. If in Patheon’s sole discretion, acting reasonably, Patheon determines that any of the information
provided by the Client in accordance with paragraphs (b) and (c) above is inaccurate or deficient in any manner whatsoever, and Patheon reasonably believes that Patheon’s standing with regulatory authorities may be jeopardized thereby
(the “Deficiencies”), Patheon shall notify the Client in writing of such Deficiencies promptly but in no event less than **** prior to Client’s applicable scheduled filing with the Regulatory Authority. The parties shall work
together in good faith to have such Deficiencies resolved prior to any pre-approval inspection. 
 (e) Client Responsibility. For
clarity, the parties agree that ****. Subject to the foregoing, Patheon will not assume any responsibility for the accuracy of any application for receipt of an approval by a Regulatory Authority. The Client is solely responsibility for the
preparation and filing of the application for approval by the Regulatory Authority and any relevant costs will be borne by the Client. 

  
 - 27 - 

****CERTAIN INFORMATION HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 









 CONFIDENTIAL TREATMENT REQUESTED 

 

 (f) Inspection by Regulatory Authorities. If Client does not ****. 

ARTICLE 8 
 TERM AND
TERMINATION 
  

	8.1	Initial Term. 

 This Agreement shall become effective as of the Effective
Date and shall continue for five years following the Effective Date (the “Initial Term”), unless terminated earlier by one of the parties in accordance herewith. This Agreement shall automatically continue after the Initial
Term for successive terms of one year each unless either party gives written notice to the other party of its intention to terminate this Agreement at least 12 months prior to the end of the then current term.  

 

	8.2	Termination for Cause. 

 (a) Either party at its sole option may terminate this
Agreement upon written notice in circumstances where the other party has failed to remedy a material breach of any of its representations, warranties or other obligations under this Agreement within **** following receipt of a written notice (the
“Remediation Period”) of said breach that expressly states that it is a notice under this Section 8.2(a) (a “Breach Notice”). 

(b) Either party at its sole option may immediately terminate this Agreement upon written notice, but without prior advance notice, to the
other party in the event that: (i) the other party is declared insolvent or bankrupt by a court of competent jurisdiction; (ii) a voluntary petition of bankruptcy is filed in any court of competent jurisdiction by such other party; or
(iii) this Agreement is assigned by such other party for the benefit of creditors. 
 (c) The Client may terminate this Agreement as to
any Product upon **** prior written notice if any governmental agency takes any action, or raises any objection, that prevents the Client from importing, exporting, purchasing or selling such Product. In addition, the Client may terminate this
Agreement **** written notice to Patheon in the event that any governmental agency in the Territory makes a decision not to grant marketing authorization to the Client with respect to Product. 

(d) Patheon may terminate this Agreement upon **** prior written notice if the Client assigns pursuant to Section 13.6 any of its rights
under this Agreement to an assignee that, in the opinion of Patheon acting reasonably, is: (i) not a credit worthy substitute for the Client; or (ii) a competitor of Patheon, where a “competitor of Patheon” means a corporation
which (a) specializes in the business of manufacturing 

  
 - 28 - 

****CERTAIN INFORMATION HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 









 CONFIDENTIAL TREATMENT REQUESTED 

 

 
pharmaceutical products for third parties and (b) does not directly or indirectly own or market pharmaceutical products in its own name. 

(e) A party may terminate this Agreement when permitted pursuant to Section 13.7. 

(f) The Client may terminate this Agreement due to Client’s discontinuation of the development of Product manufactured at the
Manufacturing Site, upon written notice delivered at least **** prior to such discontinuation. 
 (g) The Client may, upon the completion of
**** of this Agreement, terminate this Agreement at any time, for any or no reason, upon not less than **** notice to Patheon, provided that ****. The Client may, upon the completion of **** of this Agreement, terminate this Agreement at any time,
for any or no reason, upon not less than **** notice to Patheon, provided that ****. ****. 
  

	8.3	Obligations on Termination. 

 If this Agreement expires or is terminated in whole
or in part for any reason, then following the expiration or termination of this Agreement, or the end of the Wind-Down Period, if applicable (in addition to any other remedies either party may have in the event of default by the other party): 

 

	 	(a)	the Client shall take delivery of and pay for (in accordance with Section 5.6) all undelivered Products that are manufactured and/or packaged pursuant to a Firm Order, at the price in effect at the time the Firm
Order was placed. 

  

	 	(b)	the Client shall purchase, at Patheon’s cost ****, (i) the remaining Components applicable to the Products which were purchased by Patheon in contemplation of filling Firm Orders or in accordance with
Section 5.2 prior to notice of termination being given to the extent that such Components cannot be returned or used to produce product for another client; and (ii) all remaining work-in-process produced by Patheon in contemplation of
filling Firm Orders prior to notice of termination being given. 

  

	 	(c)	the Client acknowledges that no competitor of Patheon (as defined in Section 8.2(d)) shall be permitted access to the Manufacturing Site. 


  
 - 29 - 

****CERTAIN INFORMATION HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 









 CONFIDENTIAL TREATMENT REQUESTED 

 


	 	(d)	Client will make commercially reasonable efforts, at its own expense but with Patheon’s reasonable cooperation, to remove from Patheon site(s), within ****, all of Client’s Components, Inventory and supplies,
undelivered Product, chattels, equipment or other moveable property owned by Client, related to the Agreement and located at a Patheon site or that is otherwise under Patheon’s care and control (“Client Property”). If Client
fails to remove the Client Property within **** following the termination or expiration of the Agreement (or following the end of the Wind-Down Period, if applicable), Client will pay Patheon **** per pallet, per month, one pallet minimum (**** per
pallet, per month, one pallet minimum, for any of the Client Property that contains controlled substances or requires refrigeration) thereafter for storing the Client Property and will assume any third party storage charges invoiced to Patheon
regarding the Client Property. Patheon will invoice Client for the storage charges as set forth in Section 5.6 of this Agreement. 

 If
this Agreement expires or is terminated in whole or in part for any reason, then (in addition to any other remedies the Client may have in the event of default by Patheon), Patheon shall return to the Client promptly all unused Active Materials and
provide to the Client all Inventory purchased by the Client (with shipping and related expenses, if any, to be borne by the Client), following such expiration or termination or the end of the Wind-Down Period, if applicable. 

In addition, for a period of **** after the termination or expiration of this Agreement (the “Wind-Down Period”), Client may continue
to order Manufacturing, and Patheon shall continue to provide Manufacturing in accordance with such orders from Client (if any), in each case subject to the terms and conditions of this Agreement. In the event of termination by Patheon pursuant to
Section 8.2(a) due to Client’s failure to pay undisputed amounts, Patheon may require that Client pay such amounts before filling any Firm Orders and may require that Client pre-pay for any Manufacturing Services provided during the
Wind-Down Period. Furthermore, upon reasonable request by Client, Patheon will use commercially reasonable and good faith efforts to discuss with Client and come to an agreement with Client with respect to the terms for the performance of other
transition services that are reasonably requested by Client.  
 Any termination or expiration of this Agreement shall not affect any outstanding
obligations or payments due hereunder prior to such termination or expiration, nor shall it prejudice any other remedies that the parties may have under this Agreement. For greater certainty, termination of this Agreement for any reason shall not
affect the obligations and responsibilities of the parties pursuant to Articles 6, 8, 9, 10, 11, 12 and 13 and Sections 1.1, 7.3, 7.4, 7.5, 7.6 and 7.7, all of which survive any termination. 

  
 - 30 - 

****CERTAIN INFORMATION HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 









 CONFIDENTIAL TREATMENT REQUESTED 

 

 ARTICLE 9 

REPRESENTATIONS, WARRANTIES AND COVENANTS 
  

	9.1	Authority. 

 Each party covenants, represents and warrants that (i) it has
the full right and authority to enter into this Agreement, and that it is not aware of any impediment that would inhibit its ability to perform its obligations hereunder and (ii) it is a corporation duly organized, validly existing and in good
standing under the laws of its incorporating jurisdiction and has all requisite power and authority to enter into this Agreement. 
  

	9.2	Client Warranties. 

 The Client covenants, represents and warrants that, to the
Client’s knowledge as of the Effective Date: 
  

	 	(a)	the provision of the Manufacturing by Patheon solely in respect of any Product pursuant to this Agreement as directed in the new drug application for the Product that was approved by the U.S. Food and Drug
Administration or use or other disposition of any Product by Patheon as may be required to perform its obligations under this Agreement does not and will not infringe any Third Party Rights; 


 

	 	(b)	there are no actions or other legal proceedings in the Territory, the subject of which is the infringement of Third Party Rights related to any of the Specifications, or the Product or any of the Active Materials and
the Components provided by the Client to Patheon, or the sale, use or other disposition of any Product Manufactured in accordance with the Specifications; and 

  

	 	(c)	the Products, if labelled and Manufactured in accordance with the Specifications and in compliance with applicable cGMPs, Applicable Laws, the Quality Agreement and this Agreement (i) may be lawfully sold and
distributed in every jurisdiction in which the Client has Regulatory Authority approval to market such Products, (ii) ****, and (iii) will be safe for human consumption as directed on the approved labelling for such Products.


 In addition, Client covenants, represents and warrants that: 

 

	 	(i)	the Specifications for each of the Products are its or its Affiliate’s property or licensed to the Client and that the Client may lawfully disclose the Specifications to Patheon; 


 

	 	(ii)	 to the Client’s knowledge as of the Effective Date, any Intellectual Property provided by the Client to Patheon in connection with the provision
of the Manufacturing according to the Specifications (i) is the 



  
 - 31 - 

****CERTAIN INFORMATION HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 









 CONFIDENTIAL TREATMENT REQUESTED 

 


	 	
Client’s or its Affiliate’s unencumbered property or is licensed to the Client, (ii) may be lawfully used as directed by the Client, and (iii) ****; and 


 

	 	(iii)	the Specifications for all Products, as provided by the Client to Patheon, conform to all applicable cGMPs and Applicable Laws. 

  

	9.3	Patheon Warranties. 

 Patheon covenants, represents and warrants that to
Patheon’s knowledge as of the Effective Date: 
  

	 	(a)	any Intellectual Property owned by Patheon and utilized by Patheon in connection with the provision of the Manufacturing which has not been provided by Client or used at the direction of Client, (i) is
Patheon’s or its Affiliate’s unencumbered property, (ii) may be lawfully used by Patheon and (iii) does not infringe and will not infringe any Third Party Rights; 


 

	 	(b)	it and its Manufacturing Site are in compliance with all laws and regulations applicable to their operations, including, without limitation, cGMPs and Applicable Laws; 


 

	 	(c)	all Patheon personnel are fully qualified (by education, training and experience) to properly perform their tasks under this Agreement. 


In addition, Patheon covenants, represents and warrants that: 
  

	 	(i)	it shall perform the Manufacturing in accordance with the Specifications, cGMPs, Applicable Laws, the Quality Agreement and this Agreement; 


 

	 	(ii)	it will convey good title to the Product, free of all liens of any kind whatsoever; and 

  

	 	(iii)	the Products, when delivered to Client, will be Manufactured according to the Specifications. For the sake of clarity, if Patheon performs any additional steps not specified in the Specifications in Manufacturing
Products (e.g., by adding one or more additional components to the Products that are not specified in the Specifications), then Patheon will be deemed to have failed to Manufacture such Products in accordance with the Specifications.


 The warranties provided in (i), (ii) and (iii) above shall survive inspection, test, acceptance and use of the
Product. 

  
 - 32 - 

****CERTAIN INFORMATION HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 









 CONFIDENTIAL TREATMENT REQUESTED 

 


	9.4	Debarred Persons. 

 Patheon covenants that it will not in the performance of its
obligations under this Agreement use the services of any person debarred or suspended under 21 U.S.C. §335(a) or (b) or by Health Canada or any comparable European regulatory authority. Patheon represents that it does not currently have,
and covenants that it will not hire, as an officer, an employee or an independent contractor in connection with the Manufacturing any person who has been convicted of a felony under the laws of the United States for conduct relating to the
regulation of any drug product under the Federal Food, Drug, and Cosmetic Act (United States) or any comparable Canadian or European law. If Patheon becomes aware of any breaches of the Section, it will promptly notify the Client. 

 

	9.5	Permits. 

 Patheon shall maintain at all relevant times all governmental permits,
licenses, approvals, and authorities to the extent required to enable it lawfully to properly perform the Manufacturing. The Client shall be solely responsible for obtaining or maintaining, on a timely basis, any permits or other regulatory
approvals in respect of the Products or the Specifications, including, without limitation, all marketing and post-marketing approvals. 
  

	9.6	No Warranty. 

 EXCEPT AS OTHERWISE PROVIDED HEREIN,
NEITHER PATHEON NOR CLIENT MAKES ANY WARRANTY OF ANY KIND, EITHER EXPRESSED OR IMPLIED, BY FACT OR LAW, OTHER THAN THOSE EXPRESSLY SET FORTH IN THIS AGREEMENT. PATHEON MAKES NO IMPLIED WARRANTY OF FITNESS FOR A PARTICULAR PURPOSE OR WARRANTY OF
MERCHANTABILITY WITH RESPECT TO THE PRODUCTS. THE CLIENT MAKES NO WARRANTY OF FITNESS FOR A PARTICULAR PURPOSE OR WARRANTY OF MERCHANTABILITY WITH RESPECT TO THE ACTIVE MATERIALS OR COMPONENTS PROVIDED BY THE CLIENT TO PATHEON. 

ARTICLE 10 
 REMEDIES
AND INDEMNITIES 
  

	10.1	Consequential Damages. 

 To the maximum extent permitted by
applicable law, except with respect to ****, under no circumstances whatsoever shall **** be liable to the other hereunder in contract, tort, negligence, breach of statutory duty or otherwise for any indirect, punitive, incidental, reliance,
special, exemplary or consequential damages, including without limitation direct or indirect loss of profits, of production, of anticipated savings, of business or goodwill, regardless of any notice of the possibility of such damages. 

  
 - 33 - 

****CERTAIN INFORMATION HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 









 CONFIDENTIAL TREATMENT REQUESTED 

 


	10.2	Limitation of Liability. 

 (a) Active Materials.
Except as expressly set forth in Section 2.2 hereof and this Section 10.2, under no circumstances whatsoever shall Patheon be responsible for any loss or damage to the Active Materials. ****. 

(b) Maximum Liability. To the maximum extent permitted by applicable law, except with respect to ****, **** maximum liability per Year
under this Agreement for any reason whatsoever, including, without limitation, any liability resulting from a breach of its representations, warranties or other obligations under this Agreement, shall not exceed **** of the total fees paid under
this Agreement by Client to Patheon in such Year, up to a maximum value **** in the aggregate. 
  

	10.3	Patheon. 

 Patheon agrees to defend, indemnify and hold the
Client, its Affiliates and their respective officers, employees and agents harmless against any and all losses, damages, costs, claims, demands, judgments and liability to, from and in favour of third parties (other than Affiliates) resulting from,
or relating to ****. 
 If a claim occurs, the Client shall: (a) promptly notify Patheon of any such claim; (b) use commercially
reasonable efforts to mitigate the effects of such claim; (c) reasonably cooperate with Patheon in the defence of such claim; and (d) permit Patheon to control the defence and settlement of such claim, each at Patheon’s cost and
expense, provided that any settlement of such claim that does not contain an unconditional release of an indemnitee will require the prior written consent of such indemnitee, which such consent will not be unreasonably withheld. 

 

	10.4	Client. 

 The Client agrees to defend, indemnify and hold
Patheon, its Affiliates and their respective officers, employees and agents harmless against any and all losses, damages, costs, claims, demands, judgments and liability to, from and in favour of third parties (other than Affiliates) resulting from,
or relating to any claim **** 

  
 - 34 - 

****CERTAIN INFORMATION HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 









 CONFIDENTIAL TREATMENT REQUESTED 

 

 ****. 

If a claim occurs, Patheon shall: (a) promptly notify the Client of any such claims; (b) use commercially reasonable efforts to
mitigate the effects of such claim; (c) reasonably cooperate with the Client in the defence of such claim; (d) permit the Client to control the defence and settlement of such claim, each at the Client’s cost and expense, provided that
any settlement of such claim that does not contain an unconditional release of an indemnitee will require the prior written consent of such indemnitee, which such consent will not be unreasonably withheld. 

 

	10.5	Reasonable Allocation of Risk. 

 The provisions of this Agreement (including,
without limitation, this Article 10) are reasonable and create a reasonable allocation of risk having regard to the relative profits the parties respectively expect to derive from the Products. 

ARTICLE 11 

CONFIDENTIALITY 
  

	11.1	Confidentiality. 

 The provisions of the Confidentiality Agreement shall apply to
all confidential information of the parties under this Agreement, which agreement remains in effect in accordance with its terms; provided, however, that the terms of the Confidentiality Agreement shall continue to govern the parties’
obligations of confidentiality with respect to any confidential or proprietary information of the parties, for the term of this Agreement and for a period of five years following termination or expiration of this Agreement, except that the
parties’ obligations of confidentiality with respect to any confidential or proprietary information of the parties that is a trade secret under applicable law shall survive and continue in effect thereafter, in each case as though such
agreement remained in full force and effect. For the sake of clarity, the Product manufacturing process, including without limitation the Product formulation process, and the analytical methods specific to the Product are all deemed to be the trade
secrets of Client for the purposes of this Section 11.1. Promptly following any expiration or termination of this Agreement, each party shall return to the other party all originals and copies of the other party’s confidential information
and destroy all information, records 

  
 - 35 - 

****CERTAIN INFORMATION HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 









 CONFIDENTIAL TREATMENT REQUESTED 

 

 
and materials developed there from, unless otherwise expressly provided herein (e.g., under Section 7.3 (Records and Accounting by Patheon)). 

Notwithstanding the foregoing, the parties acknowledge that Client will be permitted, and may be required pursuant to the rules and
regulations promulgated under the Securities Exchange Act of 1934, as amended, to file a Current Report on Form 8-K disclosing the entry into this Agreement by Client and a brief description of the terms and conditions hereof that are material to
Client. To the extent that either party reasonably determines that it is required to make a filing or any other public disclosure (other than as set forth in the preceding sentence) with respect to this Agreement or the terms or existence hereof to
comply with the requirements, rules, laws or regulations of any applicable stock exchange, Nasdaq or any governmental or regulatory authority or body, including without limitation the U.S. Securities and Exchange Commission (the
“SEC”) (collectively, the “Disclosure Obligations”), such party shall promptly inform the other party thereof and shall use reasonable efforts to maintain the confidentiality of the other party’s confidential
information in any such filing or disclosure. To the extent that either party reasonably determines that it is required to file a copy of this Agreement to comply with the Disclosure Obligations, such party shall promptly inform the other party
thereof. Prior to making any such filing of a copy of this Agreement, the parties shall mutually agree on the provisions of this Agreement for which the parties shall seek confidential treatment, it being understood that if one party determines to
seek confidential treatment for a provision for which the other party does not, then the parties will use reasonable efforts in connection with such filing to seek the confidential treatment of any such provision. The parties shall cooperate, each
at its own expense, in such filing, including without limitation such confidential treatment request, and shall execute all documents reasonably required in connection therewith. In furtherance of the foregoing, the parties will agree as promptly as
practicable after the Effective Date on the confidential treatment request to be filed with the SEC and the redacted form of this Agreement related thereto. In furtherance thereof, any redaction reasonably requested by either party shall be included
in such filing. The parties will reasonably cooperate in responding promptly to any comments received from the SEC with respect to such filing in an effort to achieve confidential treatment of such redacted form; provided, however, that a party
shall be relieved of such obligation to seek confidential treatment for a provision requested by the other party if such treatment is not achieved after the second round of responses to comments from the SEC. This paragraph shall apply with respect
to the filing of a copy of this Agreement or any public disclosure relating to this Agreement to comply with the Disclosure Obligations, notwithstanding the provisions of the Confidentiality Agreement. 

  
 - 36 - 









 CONFIDENTIAL TREATMENT REQUESTED 

 

 ARTICLE 12 

DISPUTE RESOLUTION 
  

	12.1	Commercial Disputes. 

 If any dispute arises out of or
in connection with this Agreement (other than a dispute determined in accordance with Section 6.1(b) or a Technical Dispute), the parties shall first try to solve it amicably. In this regard, any party may send a notice of dispute to the other,
and each party shall appoint, within **** from receipt of such notice of dispute, a single representative having full power and authority to solve the dispute. The representatives so designated shall meet as necessary in order to solve such dispute.
If these representatives fail to solve the matter within **** from their appointment, or if a party fails to appoint a representative within the **** period set forth above, such dispute shall immediately be referred to the Chief Operating Officer
(or such other officer as he/she may designate) of each party who will meet and discuss as necessary in order to try to solve the dispute amicably. Should the parties fail to reach a resolution under this Section 12.1, either party may refer
the dispute to arbitration in accordance with Section 12.3. Notwithstanding the foregoing, neither party shall be prohibited from seeking injunctive or other equitable relief in any court of competent jurisdiction (including without limitation,
in any case where issues involving the protection or unauthorized use or disclosure of a party’s confidential information, trade secrets or intellectual property are involved). 

 

	12.2	Technical Dispute Resolution. 

 If a dispute (other
than disputes in relation to the matters set out in Sections 6.1(b) and 12.1) arises between the parties that is exclusively related to technical aspects of the manufacturing, packaging, labelling, quality control testing, handling, storage or other
activities under this Agreement (a “Technical Dispute”), the parties shall make all reasonable efforts to resolve the dispute by amicable negotiations. In this regard, senior representatives of each party shall, as soon as practicable and
in any event no later than **** after a written request from either party to the other, meet in good faith to resolve any Technical Dispute. If, despite such meeting, the parties are unable to resolve a Technical Dispute within a reasonable time,
and in any event within **** after such written request, the Technical Dispute shall, at the request of either party, be referred for determination to an expert in accordance with the provisions of Schedule F. In the event that the parties cannot
agree whether a dispute is a Technical Dispute, Section 12.1 shall prevail. For greater certainty, the parties agree that the release of the Products for sale or distribution pursuant to the applicable marketing approval for such Products shall
not by itself indicate compliance by Patheon with its obligations in respect of the Manufacturing and further that nothing in this Agreement (including Schedule F) shall remove or limit the authority of the relevant qualified person (as specified by
the Quality Agreement) to determine whether the Products are to be released for sale or distribution. Notwithstanding the foregoing, neither party shall be prohibited from seeking injunctive or other equitable relief in any court of competent
jurisdiction (including without limitation, in any case where issues involving the protection or 

  
 - 37 - 

****CERTAIN INFORMATION HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 









 CONFIDENTIAL TREATMENT REQUESTED 

 

 
unauthorized use or disclosure of a party’s confidential information, trade secrets or intellectual property are involved). 

 

	12.3	Arbitration. 

 If any dispute cannot be resolved in accordance with
Section 12.1, such dispute shall be finally settled by arbitration in **** using the English language in accordance with the Arbitration Rules and Procedures of Judicial Arbitration and Mediation Services, Inc. (“JAMS”) then in
effect, by one or more commercial arbitrator(s) with substantial experience in resolving complex commercial contract disputes, who may or may not be selected from the appropriate list of JAMS arbitrators. If the parties cannot agree upon the number
and identity of the arbitrators within **** following the date on which a party referred the applicable dispute to arbitration, then a single arbitrator shall be selected on an expedited basis in accordance with the Arbitration Rules and Procedures
of JAMS. Any arbitrator so selected shall have substantial experience in the pharmaceutical industry. The arbitrator(s) shall have the authority to grant specific performance and to allocate between the parties the costs of arbitration allocate
between the parties the costs of arbitration (including service fees, arbitrator fees and all other fees related to the arbitration) in such equitable manner as the arbitrator(s) may determine. The prevailing party in the arbitration shall be
entitled to receive reimbursement of its reasonable expenses (including reasonable lawyers’ fees, expert witness fees and all other expenses) incurred in connection therewith. Judgment upon the award so rendered may be entered in a court having
jurisdiction or application may be made to such court for judicial acceptance of any award and an order of enforcement, as the case may be. Notwithstanding the foregoing, each party shall have the right to institute an action in a court of proper
jurisdiction for preliminary injunctive relief pending a final decision by the arbitrator(s), provided that a permanent injunction and damages shall only be awarded by the arbitrator(s). 

 

	12.4	Dispute and Termination for Breach. 

 Notwithstanding any statement to the
contrary in this Agreement, a non-breaching party shall not be entitled to terminate this Agreement pursuant to Section 8.2(a) on account of a disputed breach until the dispute is resolved by mutual agreement or arbitration pursuant to
Section 12.3 confirming the existence of the breach. 
 ARTICLE 13 

MISCELLANEOUS 
  

	13.1	Inventions. 

 (a) For the term of this Agreement, Client hereby grants to Patheon
a non-exclusive, paid-up, royalty-free, non-sublicensable, non-transferable license of Client’s Intellectual Property, including without limitation that assigned to the Client pursuant to Section 13.1(b) below, which Patheon must use in
order to perform the Manufacturing, solely to perform the Manufacturing. Without limitation, Patheon agrees that it shall not 

  
 - 38 - 

****CERTAIN INFORMATION HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 









 CONFIDENTIAL TREATMENT REQUESTED 

 

 
use any such Client Intellectual Property or Client confidential information to enable itself or any third party to develop, make, have made, offer, sell or exploit the Products. 

(b) All Inventions (including any and all Intellectual Property Rights therein) conceived, generated, derived or reduced to practice by
Patheon in the course of performing the Manufacturing, to the extent it is related to the development, Manufacture, packaging, use or sale of the Client’s Product that is the subject of the Manufacturing or contains the Client’s
confidential information, shall be the exclusive property of Client. Patheon shall give the Client written notice, as promptly as practicable, of all such Inventions, and all such Inventions shall be deemed to be the confidential information of
Client. Patheon hereby makes, and agrees to make, any and all assignments necessary to effect, exclusively and throughout the world, the ownership by the Client of Inventions under Section 13.1(b). Patheon shall, and shall cause its employees
and contractors to, fully cooperate with and sign any documents reasonably requested by the Client to evidence, perfect or take any other action with respect to such assignments or to obtain protection, maintain or take any other action regarding
such assigned Inventions. 
 (c) All Intellectual Property generated or derived by Patheon in the course of performing the
Manufacturing to the extent it (i) is not related to the development, Manufacture, packaging, use or sale of the Client’s Product that is the subject of the Manufacturing and (ii) does not contain the Client’s confidential
information, shall be the exclusive property of Patheon (the “Broader Intellectual Property Rights”). Patheon hereby grants and agrees to grant to the Client a nonexclusive, transferable, perpetual, irrevocable, paid up,
royalty-free, worldwide right and license (including the right to sublicense) to practice and use all Broader Intellectual Property Rights solely in connection with ****  

(d) Each party shall be solely responsible for the costs of filing, prosecution and maintenance of patents and patent applications on its own
Inventions. 
  

	13.2	Intellectual Property. 

 Subject to Section 13.1, all
Intellectual Property of the Client, including without limitation any Intellectual Property that the Client owns prior to the Effective Date, shall be owned by the Client and all Intellectual Property of Patheon, including without limitation any
Intellectual Property that Patheon owns prior to the Effective Date, shall be owned by Patheon. Neither party has, nor shall it acquire, any interest in any of the other party’s Intellectual Property unless otherwise expressly agreed to in
writing. Neither party shall use any Intellectual Property of the other party, except as specifically authorized by the other party or as required for the performance of its obligations under this Agreement. Except as expressly set forth in
Section 13.1, no licenses are granted by either party, whether by implication, estoppel or otherwise, and all other rights are reserved. 

  
 - 39 - 

****CERTAIN INFORMATION HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 









 CONFIDENTIAL TREATMENT REQUESTED 

 


	13.3	Insurance. 

 Each party shall maintain commercial general
liability insurance, including blanket contractual liability insurance covering the obligations of that party under this Agreement through the term of this Agreement and for a period of **** thereafter, which insurance shall afford limits of not
less than (i) **** for each occurrence for personal injury, bodily injury or property damage liability; and (ii) **** in the aggregate per annum with respect to product and completed operations liability. If requested each party will
provide the other with a certificate of insurance evidencing the above and showing the name of the issuing company, the policy number, the effective date, the expiration date and the limits of liability. The insurance certificate shall further
provide for a minimum of **** written notice to the insured of a cancellation of, or material change in, the insurance. If a party is unable to maintain the insurance policies required under this Agreement through no fault on the part of such party,
then such party shall forthwith notify the other party in writing and the parties shall in good faith negotiate appropriate amendments to the insurance provision of this Agreement in order to provide adequate assurances, provided that in no event
shall such party terminate its insurance policies until such amendments to the insurance provision of this Agreement that are mutually agreed upon by the parties in writing are enacted. 

 

	13.4	Independent Contractors. 

 The parties are independent
contractors and this Agreement shall not be construed to create between Patheon and the Client any other relationship such as, by way of example only, that of employer-employee, principal agent, joint-venturer, co-partners or any similar
relationship, the existence of which is expressly denied by the parties hereto. 
  

	13.5	No Waiver. 

 Either party’s failure to require the other
party to comply with any provision of this Agreement shall not be deemed a waiver of such provision or any other provision of this Agreement. No waiver of any provision of this Agreement shall bind either party unless in writing and signed by the
party against which enforcement is sought. 
  

	13.6	Assignment. 

  

	 	(a)	Patheon may not assign, transfer, delegate or subcontract this Agreement or any of its rights or obligations hereunder except with the written consent of the Client, such consent not to be unreasonably withheld;
provided, however, that Patheon may arrange for subcontractors solely to perform specific testing services arising under this Agreement without the consent of the Client. Patheon shall be responsible and liable for any breaches of this Agreement by
its subcontractors. 


  
 - 40 - 

****CERTAIN INFORMATION HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 









 CONFIDENTIAL TREATMENT REQUESTED 

 


	 	(b)	Subject to Section 8.2(d), the Client may assign this Agreement or any of its rights or obligations hereunder without approval from Patheon; provided, however, that the Client shall give prior written notice of any
assignment to Patheon, and any assignee shall covenant in writing with Patheon to be bound by the terms of this Agreement. ****. 

  

	 	(c)	Notwithstanding the foregoing provisions of this Section 13.6, either party may assign this Agreement, without the consent of the other party, to any of its Affiliates or to a successor to or purchaser of all or
substantially all of its business to which the subject matter of this Agreement relates, provided that such party provides prior written notice of such assignment to the other party and the assignee executes an agreement with the non-assigning party
hereto whereby it agrees to be bound hereunder. 

  

	13.7	Force Majeure. 

 Neither party shall be liable for the failure to perform its
obligations under this Agreement if such failure is occasioned by a cause or contingency beyond such party’s reasonable control, including, but not limited to, strikes or other labour disturbances, lockouts, riots, quarantines, communicable
disease outbreaks, wars, acts of terrorism, fires, floods, storms, interruption of or delay in transportation, defective equipment, lack of or inability to obtain fuel, power or components or compliance with any order or regulation of any government
entity acting within colour of right (a “Force Majeure Event”). A party claiming a right to excused performance under this Section 13.7 shall promptly notify the other party in writing of the extent of its inability to perform,
which notice shall specify the occurrence beyond its reasonable control that prevents such performance, and shall use commercially reasonable efforts to overcome the Force Majeure Event. Notwithstanding the foregoing, if either party is prevented or
delayed in performing its obligations under this Agreement on more than (i) **** or (ii) **** in the aggregate during any ****, then the party not so affected may terminate this Agreement upon written notice to the affected party. Neither
party shall be entitled to rely on a Force Majeure Event to relieve it from an obligation to pay money (including any interest for delayed payment) which would otherwise be due and payable under this Agreement. 

 

	13.8	Additional Product. 

 Additional products may be added to this Agreement and such
additional products shall be governed by the general conditions hereof with any special terms (including, without limitation, price) governed by an addendum hereto. 

  
 - 41 - 

****CERTAIN INFORMATION HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 









 CONFIDENTIAL TREATMENT REQUESTED 

 


	13.9	Notices. 

 Any notice, approval, instruction or other written
communication required or permitted hereunder shall be sufficient if made or given to the other party by personal delivery, by telecopier or facsimile communication or by sending the same by first class mail, postage prepaid, return receipt
requested to the mailing address, or telecopier or facsimile number set forth below: 
 If to the Client: 

Vanda Pharmaceuticals Inc. 
 2200
Pennsylvania Ave NW, Suite 300E 
 Washington, DC 20037 

U.S.A. 
 Attention: Chief
Financial Officer 
 Telecopier No.: **** 

If to Patheon: 
 Patheon
Pharmaceuticals Inc. 
 2110 East Galbraith Road 

Cincinnati, OH 45237-1625 

Attention: Director of Legal Services 

Telecopier No.: **** 
 Email
address: **** 
 With a copy to: 

Patheon Inc. 
 4721 Emperor
Boulevard 
 Research Triangle Park, 

NC 27703 
 Attention: General
Counsel 
 Telecopier No.: **** 

Email address: **** 
 or to such other addresses
or telecopier or facsimile numbers provided to the other party in accordance with the terms of this Section 13.9. Notices or written communications made or given by personal delivery or by telecopier or facsimile shall be deemed to have been
sufficiently made or given when sent (receipt acknowledged), or if mailed, five days after being deposited in the United States or Canadian mail, postage prepaid, return receipt requested or upon receipt, whichever is sooner. 

  
 - 42 - 

****CERTAIN INFORMATION HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 









 CONFIDENTIAL TREATMENT REQUESTED 

 


	13.10	Severability. 

 If any provision of this Agreement is
determined by a court of competent jurisdiction to be invalid, illegal or unenforceable in any respect, such determination shall not impair or affect the validity, legality or enforceability of the remaining provisions hereof, and each provision is
hereby declared to be separate, severable and distinct. 
  

	13.11	Entire Agreement. 

 This Agreement, together with the
Schedules, the Quality Agreement and the Confidentiality Agreement, constitutes the full, complete, final and integrated agreement between the parties hereto relating to the subject matter hereof and supersedes all previous written or oral
negotiations, commitments, agreements, transactions or understandings with respect to the subject matter hereof. Any modification, amendment or supplement to this Agreement must be in writing and signed by authorized representatives of both parties.
In case of conflict, the prevailing order of documents shall be this Agreement, the Quality Agreement and the Confidentiality Agreement. 
  

	13.12	Other Terms. 

 No terms, provisions or conditions of any purchase order or other
business form or written authorization used by the Client or Patheon will have any effect on the rights, duties or obligations of the parties under or otherwise modify this Agreement, regardless of any failure of the Client or Patheon to object to
such terms, provisions, or conditions. For greater certainty, the Client’s purchase order is only effective as its unqualified commitment to obtain and pay for the Manufacturing upon the terms (and only the terms) set forth herein. 

 

	13.13	No Third Party Benefit or Right. 

 For greater certainty, nothing in this
Agreement shall confer or be construed as conferring on any third party any benefit or the right to enforce any express or implied term of this Agreement. 
  

	13.14	Execution in Counterparts. 

 This Agreement may be executed in two counterparts,
by original or facsimile signature, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 
  

	13.15	Governing Law. 

 This Agreement shall be construed and enforced in accordance with
the laws of the State of ****, without regard to its conflicts of law provisions. The UN Convention on Contracts for the International Sale of Goods shall not apply to this Agreement. Unless expressly provided otherwise, each right and remedy in
this Agreement is in addition to any other right or remedy, at law or in equity, and the exercise of one right or remedy will not be deemed a waiver of any other right or remedy. 

  
 - 43 - 

****CERTAIN INFORMATION HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 









 EXHIBIT 10.53 

CONFIDENTIAL TREATMENT REQUESTED 
  

 
  

 IN WITNESS WHEREOF, the duly authorized representatives of the parties have executed this
Agreement as of the date first written above. 
 PATHEON PHARMACEUTICALS INC. 

 

							
	By	 	     /s/ Dean Wilson
	 	


					
	Name:	 	Dean Wilson	 	
	Title:	 	VP corporate controller	 	1/24/2014
	
	 VANDA PHARMACEUTICALS INC.



					
			
	 By
	 	     /s/ M. H. Polymeropoulos, M.D.
	 	


					
	 Name:
	 	M. H. Polymeropoulos, M.D.	 	
	 Title:
	 	CEO	 	


  
 - 44 - 

****CERTAIN INFORMATION HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 









 EXHIBIT 10.53 

CONFIDENTIAL TREATMENT REQUESTED 
  

 
  

 SCHEDULE A 

PRODUCT LIST 
 Products

 HetliozTM 20 mg Capsules in **** 

Specifications 
 Prior to the commencement of
commercial manufacturing of Product under this Agreement, the Client shall provide Patheon with copies of the FDA approved NDA Specifications. If the Specifications provided are subsequently amended, then the Client shall provide Patheon with
revised copies of such revised Specifications. Upon acceptance of the revised Specifications pursuant to Section 4.4, Patheon shall provide the Client with a signed and dated receipt evidencing such acceptance of the revised Specifications by
Patheon. 

  
 - 45 - 

****CERTAIN INFORMATION HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 









 CONFIDENTIAL TREATMENT REQUESTED 

 

 SCHEDULE B 

COMMERCIAL PRICING 
 **** 

 

											
	 	  	 	  	 	  	 ****

	 ****
	  	 ****
	  	 ****
	  	 ****
	  	 ****
	  	 ****

	 ****
	  	****	  	****	  	****	  	****	  	****
						
	 ****
	  	****	  	****	  	****	  	****	  	****
						
	 ****
	  	****	  	****	  	****	  	****	  	****

 **** 

  
 - 46 - 

****CERTAIN INFORMATION HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 









 CONFIDENTIAL TREATMENT REQUESTED 

 

 **** 
  

							
	 ****
	  	 ****
	  	 ****
	  	 ****

	 ****
	  	****	  	****	  	
				
	 ****
	  	****	  	****	  	
				
		  		  		  	
				
	 ****
	  		  	****	  	
				
	 ****
	  		  		  	****

 **** 

  
 - 47 - 

****CERTAIN INFORMATION HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 









 CONFIDENTIAL TREATMENT REQUESTED 

 


			
	 ****
	  	 ****

	 ****
	  	****
		
	 ****
	  	****
		
	 ****
	  	****

     **** 
  

											
	                ****	  	 ****
	  	 	  	 	  	 	  	 
	                 ****
	  	****	  		  		  		  	
						
	                 ****
	  	****	  		  		  		  	
						
	                 ****
	  	****	  		  		  		  	
						
	                 ****
	  	****	  		  		  		  	

     **** 
  

											
	                ****	  	 ****
	  	 	  	 	  	 	  	 
	                 ****
	  	****	  		  		  		  	
						
	                 ****
	  	****	  		  		  		  	
						
	                 ****
	  	****	  		  		  		  	
						
	                 ****
	  	****	  		  		  		  	

 **** 
  

							
	                                     
       ****	  	 ****
	  	 ****
	  	 ****

	 ****
	  	****	  	****	  	****
				
	 ****
	  	****	  	****	  	****
				
	 ****
	  	****	  	****	  	****


  
 - 48 - 

****CERTAIN INFORMATION HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 









 CONFIDENTIAL TREATMENT REQUESTED 

 

 **** 
  

			
	 ****
	 	 
	 ****
	 	 
		
	 ****
	 	
		
	 ****
	 	
		
	 ****
	 	
		
	 ****
	 	
		
	 ****
	 	
		
	 ****
	 	
		
	 ****
	 	
		
	 ****
	 	
		
	 ****
	 	

 **** 

  
 - 49 - 

****CERTAIN INFORMATION HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 









 CONFIDENTIAL TREATMENT REQUESTED 

 

 SCHEDULE C 

STABILITY TESTING 
 **** 

 

			
	****	  	****
		
	****	  	****
		
	****	  	

  

															
	 ****
	 	****	 	****	 	****	 	****	 	****	 	****	 	****
	****	 	****	 	****	 	****	 	****	 	****	 	****	 	****
								
	****	 	****	 	****	 	****	 	****	 	****	 	****	 	****
								
	****	 	****	 	****	 	****	 	****	 	****	 	****	 	****
								
	****	 	****	 	****	 	****	 	****	 	****	 	****	 	****
								
	****	 	****	 	****	 	****	 	****	 	****	 	****	 	****
								
	****	 	****	 	****	 	****	 	****	 	****	 	****	 	****
								
	****	 	****	 	****	 	****	 	****	 	****	 	****	 	****
								
	****	 	****	 	****	 	****	 	****	 	****	 	****	 	****
								
	****	 	****	 	****	 	****	 	****	 	****	 	****	 	****
								
	****	 	****	 	****	 	****	 	****	 	****	 	****	 	****
								
	****	 	****	 	****	 	****	 	****	 	****	 	****	 	****
								
	****	 	****	 	****	 	****	 	****	 	****	 	****	 	****
								
	****	 	****	 	****	 	****	 	****	 	****	 	****	 	****


  
 - 50 - 

****CERTAIN INFORMATION HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 









 EXHIBIT 10.53 

CONFIDENTIAL TREATMENT REQUESTED 
  

 
  

 SCHEDULE D 

 

			
	                            ****	  	                            ****
	****	  	****


			
	 ****
  
	  	
	 ****
	  	 ****

	****	  	****
		
	****	  	

  

			
	****                                      
                                  	  	****


  
 - 51 - 

****CERTAIN INFORMATION HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 









 CONFIDENTIAL TREATMENT REQUESTED 

 

 SCHEDULE E 

BATCH NUMBERING & EXPIRATION DATES 

**** 

  
 - 52 - 

****CERTAIN INFORMATION HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 









 EXHIBIT 10.53 

CONFIDENTIAL TREATMENT REQUESTED 
  

 
  

 SCHEDULE F 

TECHNICAL DISPUTE RESOLUTION 
 ****


  
 - 53 - 

****CERTAIN INFORMATION HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 









 CONFIDENTIAL TREATMENT REQUESTED 

 

 **** 

  
 - 54 - 

****CERTAIN INFORMATION HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 









 EXHIBIT 10.53 

CONFIDENTIAL TREATMENT REQUESTED 
  

 
  

 SCHEDULE G 

QUALITY AGREEMENT 

  
 - 55 - 









 EXHIBIT 10.53 

CONFIDENTIAL TREATMENT REQUESTED 
  

 
  

 SCHEDULE H 

QUARTERLY ACTIVE MATERIALS INVENTORY REPORT 

**** 

  
 - 56 - 

****CERTAIN INFORMATION HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 









 EXHIBIT 10.53 

CONFIDENTIAL TREATMENT REQUESTED 
  

 
  

 SCHEDULE I 

REPORT OF ANNUAL ACTIVE MATERIALS INVENTORY RECONCILIATION AND 

CALCULATION OF ACTUAL ANNUAL YIELD 

**** 

  
 - 57 - 

****CERTAIN INFORMATION HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. 









 CONFIDENTIAL TREATMENT REQUESTED 

 

 **** 

  
 - 58 - 

****CERTAIN INFORMATION HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.